Company Profile of PONY Biomedicine

Introduction to PONY Testing Group PONY Testing Group Co., Ltd. was founded in 2002, headquartered in Beijing and restructured by the National Research Institute. It was listed on the ChiNext board on September 16, 2020, with stock code 300887. The group has now developed into a large-scale comprehensive testing group with over 8000 employees, 30 large-scale experimental bases, and a business network consisting of more than 100 wholly-owned subsidiaries and branches throughout the country. Puni Testing has been recognized as a national level enterprise technology center, a government approved biopharmaceutical engineering laboratory, and multiple postdoctoral research workstations. In January 2023, Puni Testing Group successfully acquired Hubei Zhongjia Synthetic Pharmaceutical Co., Ltd., a modern pharmaceutical enterprise that integrates research and development, production, and marketing of chemical raw materials. It has a GMP production system and production capacity for raw materials, and has opened up the "last mile" of a one-stop biopharmaceutical technology platform. At this point, Puni testing can provide full process technical support for the research and development of biopharmaceuticals, including small-scale, pilot, and scale-up, enhancing the group's comprehensive competitiveness. Hubei Zhongjia Synthetic Pharmaceutical Co., Ltd. was established in November 2011 with a registered capital of 17 million yuan. It is located in Yuekou Industrial Park, Tianmen City, Hubei Province, covering an area of 35000 square meters. The albendazole, propyl gallate, and pyrrolidone sodium produced by Zhongjia Synthetic have all obtained the "Drug Production License" and production approval number issued by the National Food and Drug Administration. The raw material drug production workshop has passed GMP certification, and production is strictly organized in accordance with GMP regulations, continuously improving the standardization and standardization of drug production management. Striving for excellence and continuous improvement to ensure the quality of the company's products. Zhongjia Synthetic Pharmaceutical is the main manufacturer of pharmaceutical grade albendazole raw materials in China. The quality of its main product, albendazole, has reached the international leading level and can simultaneously meet the pharmacopoeia standards of China, the United States, Europe and other countries around the world. In 2017, the company donated a batch of albendazole to the World Health Organization for the production of international pharmacopoeia reference materials, which received recognition and appreciation from relevant departments of the World Health Organization.